FibroBiologics Granted Extension by Nasdaq to Regain Compliance
FibroBiologics, Inc. (FBLG)
Company Research
Source: GlobeNewswire
HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it received a favorable determination from a Nasdaq Hearings Panel granting an extension to regain compliance for the continued listing of the Company’s common stock on The Nasdaq Capital Market (“Nasdaq”). This provides FibroBiologics with a clear path to maintaining its listing on Nasdaq, subject to the Company satisfying the following conditions: meeting the equity standard of $2.5 million required under Nasdaq Listing Rule 5550(b)(1), as an alternative to the $35 million minimum Market Value of Listed Securities as set forth in Listing Rule 5550(b)(2), on or before February 27, 2026; meeting the minimum bid price requirement of $1.00 p
Show less
Read more
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics to Present at the BIO Investment & Growth SummitGlobeNewswire
- FibroBiologics (FBLG) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
- FibroBiologics (FBLG) had its price target lowered by D. Boral Capital from $15.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown UniversityGlobeNewswire
FBLG
Earnings
- 5/14/25 - Miss
FBLG
Analyst Actions
- 2/26/26 - HC Wainwright
FBLG
Sec Filings
- 2/24/26 - Form 10-K
- 2/23/26 - Form 8-K
- 2/6/26 - Form 8-K
- FBLG's page on the SEC website